Seeking Alpha

NC-stat DPNCheck regulatory submission in China

  • NeuroMetrix (NURO) applies for marketing clearance in China for its NC-stat DPNCheck peripheral neuropathy detection device. Once cleared, it will be marketed by the company's partner for Asian markets Omron Healthcare.
  • Approximately 100M Chinese have diabetes which comprises almost one quarter of the world total, making it the largest peripheral neuropathy diagnostic market by volume.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs